Clinical Trial Update: Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis [Phase 2]

View source ↗

Summary

Phase 2 trial of Olaparib in men with high-risk biochemically recurrent prostate cancer after radical prostatectomy, including integrated biomarker analysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-03